Clinical Use of Pregabalin in General Practice in Catalonia, Spain: A Population-Based Cross-Sectional Study

Viñas-Bastart, Montserrat; Oms-Arias, Míriam; Pedraza-Gutiérrez, Àfrica; Lizano-Díez, Irene; Modamio, Pilar; Mariño, Eduardo L.

doi:10.1093/pm/pnx159

Cited by 5 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Average daily dosing ranges from 50 to 600mg/day. This variability may facilitate the titration in fibromyalgia treatment in addition to making its maintenance more flexible, adjusting the dosage to each patient 28,38,[40][41][42][43] .…”

Section: Pregabalin In Sleep Disturbances In Cases Of Fibromyalgiamentioning

confidence: 99%

Does pregabalin improve sleep disorders in fibromyalgia?

Poluha

Grossmann

2018

Brazilian Journal of Pain

View full text Add to dashboard Cite

BACKGROUND AND OBJECTIVES: Fibromyalgia is a chronic generalized pain syndrome accompanied by somatic symptoms, mainly represented by sleep disorders. Pregabalin is the main agent among pharmacological treatments. CONTENTS: An electronic search was performed in the databases Lilacs, Pubmed/Medline, Scielo and ScienceDirect. The keywords used in English and Portuguese were "fibromyalgia"; "sleep disorder", "treatment"; "pregabalin"; "medicine"; "fibromialgia"; "distúrbios do sono", "tratamento"; "pregabalina"; "fármacos". Only articles of literature review, systematic review, meta-analysis and randomized clinical studies published between October 1992 and May 2018 were included. CONCLUSION: Pregabalin is efficient and safe in the management of sleep disorders in patients with fibromyalgia because it reduces the number of awakenings and increases sleep duration.

show abstract

Section: Pregabalin In Sleep Disturbances In Cases Of Fibromyalgiamentioning

confidence: 99%

Does pregabalin improve sleep disorders in fibromyalgia?

Poluha

Grossmann

2018

Brazilian Journal of Pain

View full text Add to dashboard Cite

show abstract

“…Evidence-based guidelines, such as the Neuropathic Pain Special Interest Group (NeuPSIG) of the International Association for the Study of Pain (IASP) [1,18], recommend pregabalin as a firstline treatment for NeP, alongside other therapeutics including tricyclic antidepressants, serotonin-noradrenaline reuptake inhibitors, and gabapentin [18]. However, nonspecialist prescribers, i.e., general practitioners (GPs) or primary care physicians (PCPs), can be uncertain with initiating and/or titrating therapeutics used for chronic NeP [19][20][21]. There is a lack of clinical studies to help guide these physicians in the optimal sequence of therapy for a specific patient [6].…”

Section: Introductionmentioning

confidence: 99%

Pregabalin for neuropathic pain in primary care settings: recommendations for dosing and titration

Freynhagen

Baron

Kawaguchi

et al. 2021

Postgraduate Medicine

View full text Add to dashboard Cite

Pregabalin is one of the first-line treatments approved for the management of neuropathic pain (NeP). While many patients benefit from treatment with pregabalin, they are often treated with suboptimal doses, possibly due to unfamiliarity around prescribing the drug and/or side effects that can occur with up-titration. This narrative review discusses key aspects of initiating, titrating, and managing patients prescribed pregabalin therapy, and addresses concerns around driving and the potential for abuse, as well as when to seek specialist opinion. To ensure that patients derive maximum therapeutic benefit from the drug, we suggest a 'low and slow' dosing approach to limit common side effects and optimize tolerability alongside patients' expectations. When requiring titration to higher doses, we recommend initiating 'asymmetric dosing,' with the larger dose in the evening. Fully engaging patients in order for them to understand the expected timeline for efficacy and side effects (including their resolution), can also help determine the optimal titration tempo for each individual patient. The 'low and slow' approach also recognizes that patients with NeP are heterogeneous in terms of their optimal therapeutic dose of pregabalin. Hence, it is recommended that general practitioners closely monitor patients and up-titrate according to pain relief and side effects to limit suboptimal dosing or premature discontinuation.

show abstract